Mammoth Biosciences Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
169
- Latest Deal Type
-
Series D1
- Latest Deal Amount
-
$107M
- Investors
-
37
Mammoth Biosciences General Information
Description
Operator of a biotechnology company intended to develop long-term curative therapies and decentralized precision diagnostics. The company leverages its proprietary ultracompact proteins for in vivo gene editing in difficult-to-reach tissues utilizing nuclease applications, including base editing, gene writing, and epigenetic editing, enabling healthcare professionals to improve patients' lives.
Contact Information
Website
www.mammoth.bioCorporate Office
- 1000 Marina Boulevard
- Suite 600
- Brisbane, CA 94005
- United States
Corporate Office
- 1000 Marina Boulevard
- Suite 600
- Brisbane, CA 94005
- United States
Mammoth Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series D1) | 22-Apr-2024 | $107M | Completed | Generating Revenue | ||
| 9. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 8. Later Stage VC (Series D) | 09-Sep-2021 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series C) | 19-May-2020 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series B) | 30-Jan-2020 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series A) | 30-Jul-2018 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 24-Jan-2018 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 15-May-2017 | Completed | Startup | |||
| 2. Accelerator/Incubator | 01-Jan-2017 | Completed | Startup | |||
| 1. University Spin-Out | 01-Jan-2017 | Completed | Startup |
Mammoth Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D-2 | ||||||||
| Series D-1 | ||||||||
| Series D | ||||||||
| Series C-1 | ||||||||
| Series C | ||||||||
| Series B-1 | ||||||||
| Series B | 13,631,447 | $0.000100 | 8% | $2.7 | $2.7 | 1x | $2.7 | 13.19% |
| Series A | 18,051,205 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 17.47% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Mammoth Biosciences Comparisons
Industry
Financing
Details
Mammoth Biosciences Competitors (30)
One of Mammoth Biosciences’s 30 competitors is Metagenomi Therapeutics, a Formerly VC-backed company based in Emeryville, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Metagenomi Therapeutics | Formerly VC-backed | Emeryville, CA | ||||
| Editas Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Arbor Biotechnologies | Venture Capital-Backed | Cambridge, MA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Adaptive Biotechnologies | Formerly VC-backed | Seattle, WA |
Mammoth Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Mammoth Biosciences Patents
Mammoth Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026112324-A1 | Methods and compositions for snp detection and genotyping | Pending | 22-Nov-2024 | ||
| WO-2026050318-A1 | Compositions for the modification of the human apoc3 gene | Pending | 28-Aug-2024 | ||
| WO-2026050318-A9 | Compositions for the modification of the human apoc3 gene | Pending | 28-Aug-2024 | ||
| WO-2025137123-A1 | Compositions and methods for circularizing donor nucleic acids | Inactive | 20-Dec-2023 | ||
| US-20250177569-A1 | Compositions for the modification of the human nras and kras genes | Pending | 04-Dec-2023 | A61K48/005 |
Mammoth Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Mammoth Biosciences Investors (37)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 369 Growth Partners | Venture Capital | Minority | ||
| Newmay Ventures | Venture Capital | Minority | ||
| Regeneron Pharmaceuticals | Corporation | Minority | ||
| Berkeley Frontier Fund | Venture Capital | Minority | ||
| California Innovation Fund | Venture Capital | Minority |
Mammoth Biosciences FAQs
-
When was Mammoth Biosciences founded?
Mammoth Biosciences was founded in 2017.
-
Where is Mammoth Biosciences headquartered?
Mammoth Biosciences is headquartered in Brisbane, CA.
-
What is the size of Mammoth Biosciences?
Mammoth Biosciences has 169 total employees.
-
What industry is Mammoth Biosciences in?
Mammoth Biosciences’s primary industry is Drug Discovery.
-
Is Mammoth Biosciences a private or public company?
Mammoth Biosciences is a Private company.
-
What is the current valuation of Mammoth Biosciences?
The current valuation of Mammoth Biosciences is .
-
What is Mammoth Biosciences’s current revenue?
The current revenue for Mammoth Biosciences is .
-
How much funding has Mammoth Biosciences raised over time?
Mammoth Biosciences has raised $375M.
-
Who are Mammoth Biosciences’s investors?
369 Growth Partners, Newmay Ventures, Regeneron Pharmaceuticals, Berkeley Frontier Fund, and California Innovation Fund are 5 of 37 investors who have invested in Mammoth Biosciences.
-
Who are Mammoth Biosciences’s competitors?
Metagenomi Therapeutics, Editas Medicine, Arbor Biotechnologies, CRISPR Therapeutics, and Adaptive Biotechnologies are some of the 30 competitors of Mammoth Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
